A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities

Zahra Nekoukar, Minoo Moghimi, Ebrahim Salehifar

Department of Clinical Pharmacy, Mazandaran University of Medical Sciences, Pharmaceutical Sciences Research Center, Hemoglobinopathy Institute, Department of Clinical Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran

Abstract

Chronic myeloid leukemia (CML), a myeloproliferative disorder caused by the over activity of BCR-ABL1 (breakpoint cluster region-Abelson), has been successfully treated by Tyrosine kinase inhibitors (TKIs). While imatinib is known as the first-line treatment of CML, in some cases other TKIs including dasatinib, nilotinib, bosutinib, and ponatinib may be preferred. Dasatinib, a second-generation TKI, inhibits multiple family kinases including BCR-ABL, SRC family kinases, receptor kinases, and TEC family kinases. It is effective against most imatinib-resistant cases except T315I mutation. Despite the superiority of dasatinib in its hematologic and cytogenetic responses in CML compared to imatinib, its potentially harmful pulmonary complications including pleural effusion (PE) and pulmonary arterial hypertension (PAH) may limit its use. Appropriate management of these serious adverse reactions is critical in both improving the quality of life and the outcome of the patient. In this narrative review, we will scrutinize the pulmonary complications of dasatinib and focus on the management of these toxicities.

Key Words

Dasatinib, Pleural effusion, Pulmonary arterial hypertension, Chronic myeloid leukemia, Pharmacotherapy

INTRODUCTION

An overview to CML

Chronic myeloid leukemia (CML) is a myeloproliferative disorder associated with Philadelphia chromosome t(9;22)(q34;q11) and/or the BCR-ABL1 (breakpoint cluster Region-Abelson) fusion gene. Cytogenetic abnormality results in the expression of BCR-ABL1 protein with a constitutive tyrosine kinase (TK) activity. The incidence of CML is one to two cases per 100,000 adults. BCR-ABL1 promotes cell proliferation by downstream pathways like MYC, STAT, RAS, RAF and JUN kinases. Although it can occur at any age, the median age of patients is 67 years.

The disease is defined as 3 phases: chronic phase (CP), accelerated phase (AP), and blast phase (BP). Uncontrolled chronic phase will lead to accelerated and blast phases of CML within 3 to 5 years. The diagnosis of CML is based on the detection of the Philadelphia chromosome, the BCR-ABL1 fusion gene or the BCR-ABL1 fusion mRNA by conventional cytogenetics, fluorescence in situ hybridization (FISH) analysis or reverse transcriptase polymerase chain reaction (RT-PCR) on peripheral blood or bone marrow samples. About 50% of patients are asymptomatic at the time of diagnosis and others have non-specific symptoms such as left upper quadrant pain, fullness, fatigue, malaise and night sweats. Bleeding is likely to occur when significant thrombocytopenia is present.

Evolution of treatment of CML

Previously, recombinant interferon-alpha, low dose of cytarabine and allogeneic hematopoietic cell transplantation (HCT) were used as standard of care for CML. HCT may be associated with a definite cure but complications and related mortality limits the utility. Over the past 2 decades, patients with Ph+/BCR-ABL1 CML have been successfully treated by tyrosine kinase inhibitors (TKIs). TKIs have been effectively used against neoplasms associated with inappropriate activation of different tyrosine kinases and were associated with a better complete cytogenetic response (CCyR) compared to other treatments. In newly diagnosed CML cases who receive TKIs as standard treatment, the 5-year survival rates increased from 40-50% to 90% so that...
the lifespan of CML patients is nearly the same as general population [7, 8].

**Different TKIs in CML**

Imatinib, nilotinib, dasatinib, bosutinib, and ponatinib are TKIs approved by the US Food and Drug Administration (FDA) for treatment of patients with CML. These agents are different in efficacy and toxicity. Selection of a TKI depends on particular clinical feature and toxicity profile of each agent and also patient’s age, underlying diseases, and the goal of treatment [4, 9]. Imatinib 400 mg daily is the gold standard for treatment of CML. In patients who did not achieve clinical response or those did not tolerate treatment, higher doses (600 or 800 mg daily) is not recommended due to more adverse effects without improvement of clinical outcomes. Some second generation TKIs including nilotinib (300 mg twice daily) and dasatinib (100 mg once daily) may be used as the first line treatment [10, 11]. Efficace et al. [12] reported a better quality of life of chronic phase CML patients who were treated with dasatinib at the first line compared to imatinib. Bosutinib, another second generation TKI is approved for CML cases that are intolerant or resistant to prior first line therapies. Recent evidences from BFORE trial showed better clinical responses for bosutinib 400 mg once daily in comparison with imatinib 400 mg in newly diagnosed Ph+ BCR-ABL1 CML [13]. Ponatinib is the only TKI that was approved for CML patients with T315I mutation. It is also used as a second line treatment for cases who were resistant to imatinib, or experienced treatment failure/intolerance to other TKIs such as dasatinib, nilotinib or other second line agents [4].

**TKIs-induced pulmonary toxicities**

The incidence of pulmonary toxicities of TKIs is less than 1% [14]. The most reported toxicities were pulmonary artery hypertension (PAH), pleural effusion (PE), interstitial lung disease (ILD), pulmonary edema, chylothorax, cough, pneumonitis, bronchospasm and upper respiratory tract infection [15-21]. Most of these adverse reactions need discontinuing treatment and initiating a medical intervention [22]. Although PAH was not reported by using imatinib or nilotinib and rarely reported with lapatinib, ponatinib, and bosutinib, it is a known complication of dasatinib [23-27]. PE mostly occurs following treatment with dasatinib and bosutinib which could alter the patient’s compliance to the therapy. TKIs associated ILD is less likely to happen in which different histological markings lead to various clinical presentations [28]. In the following sections, we will focus on dasatinib-induced PE and PAH as two major pulmonary toxicities and their management will be discussed.

**METHODS**

We searched scientific databases for indexed studies on PubMed and Google-scholar based on the terms: “dasatinib”, “chronic myeloid leukemia”, “tyrosine kinase inhibitors”, “pulmonary arterial hypertension”, “pleural effusion”, and “pulmonary toxicity”. The Boolean operators (AND/OR) were also used to combine search terms. All case reports, case series, clinical trials, and relevant review articles were selected without limitation of the year of publication. Studies in languages other than English and those with only abstracts available were excluded.

**DASATINIB**

**Efficacy in CML**

Dasatinib, an oral potent second generation TKI, was approved in 2010 by FDA for management of newly diagnosed CML patients who are in chronic phase (100 mg once daily), and any phases of disease that is resistant or intolerant to previous treatment (70 mg twice daily) [29]. It is also used with 70 mg twice daily regimen in Ph+ acute lymphoblastic leukemia (ALL) [30-32]. Dasatinib inhibits BCR-ABL, SRC (v-src sarcoma viral oncogene homolog) family kinases (including SRC, LCK, LYN, FYN, YES, HCK, FGR, BLK, YRK), receptor kinases (c-KIT, PDGFRα, DDR 1 and 2, c-FMS, ephrin receptors), and TEC family kinases (TEC and BTK) [20, 30]. Dasatinib with its thiazole-carboxamide structure binds to the both active and inactive conformations of BCR-ABL1 while imatinib only inhibits inactive form [33]. It was efficacious on 18 out of 19 imatinib-resistant BCR-ABL mutations with the exception of T315I mutation [33, 34]. Results obtained from numerous prior studies demonstrated that dasatinib is superior to imatinib in terms of clinical outcomes including hematologic and cytogenetic responses with more potent activity against BCR-ABL (325 to 350 folds) [29, 31]. Various investigations have shown clinical efficacy of dasatinib over imatinib in both resistant and intolerant patients and also in newly diagnosed CML cases [29]. DASISION study was performed on treatment-naïve chronic phase CML patients to compare imatinib and dasatinib at the dose of 400 and 100 mg once daily, respectively. Analysis of long term results showed that dasatinib was associated with a faster and profound molecular response (MR), major molecular response and CCyR. Progression-free survival (PFS) and overall survival (OS) were high in both groups however patients in dasatinib group achieved an earlier response with a fewer CML-related death [35]. Another trial evaluated efficacy of different doses of dasatinib in imatinib-resistant or intolerant patients. The results showed that 100 mg daily dosing was associated with a better tolerability. A faster treatment response and also improvement in long term clinical benefits was reported with dasatinib [8].

**Dasatinib adverse effects**

Despite a dramatic improvement of survival of CML patients following approval of TKIs, various early and late adverse effects including gastrointestinal, cardiovascular, endocrine, hematologic and pulmonary toxicities were reported [36-39]. Gastrointestinal adverse effects include nausea and
vomiting, diarrhea, abdominal pain, hemorrhagic colonic ulcers, acute hepatitis, anorexia, dyspepsia, and gastrointestinal bleeding as a result of platelet dysfunction. The mucosal inflammation including mucositis/stomatitis, constipation, acute pancreatitis, abdominal distension and colitis were seen in less than 10% of the cases. Endocrine disorders were gynecomastia, irregular menses, hypoglycemia, hyperglycemia and increased triglyceride and cholesterol levels [30, 32, 38, 40-42]. The most common cardiovascular effects were fluid retention, pericardial effusion, and to a lesser extent, cardiac dysfunction including cardiomegaly, angina, congestive heart failure and cardiac dysrhythmia including tachycardia and QTC prolongation [43-46]. Anemia, thrombocytopenia and neutropenia were reported with dasatinib which are most observed in Ph+ ALL patients and advanced phase CML patients compared to chronic phase. Thrombocytopenia is more clinically substantial and may result in central nervous system hemorrhage and gastrointestinal bleeding so that it is recommended to administrate dasatinib with caution in those receiving anticoagulation or antiplatelet agents [38,46].

Dasatinib-induced pleural effusion: Pleural Effusion (PE) is a lymphocyte-predominant exudate, which has been observed with all BCR-ABL TKIs, but dasatinib has the most frequency (up to 35%) [14, 16, 47]. According to the Quintás-Cardama et al. [47] about 50% of dasatinib-induced PE cases were in accelerated phase of leukemia. Autoimmune inhibition of the PDGFR β which causes fluid retention has been suggested as involved mechanism of dasatinib-induced PE [48]. The occurrence of PE is one important cause of treatment withdrawal [49, 50]. The phase 3 of final DASISION trial has shown that the incidence of PE following use of TKIs were more common with dasatinib (28%) versus imatinib (0.8%) [35]. More dasatinib-induced PE occurred at the 5 years study results (29%) compared to the first year (10%). Most PE cases were in grade 1 (asymptomatic) or 2 (symptomatic; intervention such as diuretics or ≤2 therapeutic thoracenteses indicated) [51]. The incidence of PE was not associated with a negative effect on achieving clinical CCyR [35, 52]. Predisposing factors for PE were twice-daily dasatinib regimen, the initial daily dose of dasatinib (140 mg vs. 100 mg), other pulmonary diseases, the age of patient (60% in patients age ≥ 65 yr vs. 25% in patients younger than 65 yr), skin rash, hypercholesterolemia, as well as presence of hypertension, and a history of cardiac or autoimmune diseases. Based on the higher incidence of PE with twice-daily dosing of dasatinib, once-daily dosing regimen is now recommended for treatment of CML and ALL [16]. Univariate analysis of association between disease phase and development of PE revealed that treatment with dasatinib in accelerated phase and blast crisis is a risk factor for developing PE and patients whom treated particularly with higher doses of dasatinib should be accurately monitored for PE sign and symptoms [47]. Several studies reported that hypertension is a major comorbidity in patients with PE [35, 47, 49, 53, 54]. The animal model of dasatinib-induced PE indicated that in a dose-dependent manner, dasatinib could lead to altered pulmonary endothelial permeability which was reversible by decreasing dose or holding treatment and switching into other TKI. It was proposed that changes in intercellular junctions along with production of stress fibers in cytoplasm and reactive oxygen species (ROS) involve in the development of dasatinib-induced PE [54, 55].

Dasatinib-induced chylolothorax is a rare pulmonary adverse event that is a subgroup of PE and defined as triglycerides and cholesterol concentrations of pleural fluid more than 110 mg dL⁻¹ (1.24 mmol L⁻¹) and less than 200 mg dL⁻¹ (5.18 mmol L⁻¹), respectively [56]. Chylothorax results from obstruction or disruption of thoracic duct which leads to leakage of chyle into pleural space [19]. Despite aforementioned explanations, the exact molecular mechanism of PE and chylolothorax has not been elucidated and needs further investigation [54, 57].

Dasatinib-induced pulmonary arterial hypertension: Pulmonary Arterial Hypertension (PAH) is one of the most severe pulmonary toxicities of TKIs and was mostly reported with dasatinib [14, 58]. PAH is a rare complication (0.45%) which is defined as increased mean pulmonary arterial pressure (mPAP) > 25 mmHg at rest or > 30 mmHg by exercising in the absence of elevated pulmonary capillary wedge pressure (PCWP) and pulmonary vascular resistance (PVR) > 3 woods units that leads to right ventricular and progressively left ventricular failure [59]. In the presence of dyspnea, atypical chest pain, fatigue or unexplained syncope, Chest X-Ray (CXR) or trans-thoracic echocardiography (TTE) should be used and if PAH was proposed, right heart catheterization (RHC) should be performed to confirm the diagnosis [22]. On the basis of RHC results, PAH is determined as elevated right ventricular systolic pressure (RVSP) and/or pulmonary arterial systolic pressure above 40 mmHg. In addition, Toya et al. [60] conducted a study on 60 dasatinib treated cases and investigated whether which of the following items is more reliable for early predicting PAH: 1) recent electrocardiographic changes indicating right ventricular pressure overload; 2) estimated systolic pulmonary arterial pressure > 40 mmHg measured by Doppler echocardiography; 3) computed tomography (CT)-measured pulmonary artery to aorta diameter (PaD/AoD) ratio > 1; and 4) mean pulmonary arterial pressure > 25 mmHg and pulmonary artery wedge pressure < 15 mmHg measured by right heart catheterization. Although an increase in PaD/AoD ratio measured by CT imaging occurred in all cases, it was found that a significantly higher PaD/AoD ratio (> 1) at baseline was seen in those developed PAH and it could be used as an early predictor of dasatinib-induced PAH. PAH happens on prolonged treatment with dasatinib (19-52 mo), confirming the chronicity nature of the involved pathological mechanism. Dasatinib-induced PAH predominantly occurs in women and is often concomitant with previous or present PE [15]. PAH in a CML patient may be drug-induced (group 1) or related to CML pathophysiology [15, 61-63]. It has been demonstrated that treatment with dasatinib causes a dose-dependent increase in production of mitochondrial ROS; resulting to endothelial apoptosis, pulmonary endothelial dysfunction and...
Another proposed mechanism is related to SRC family kinases and platelet-derived growth factor (PDGF) pathway [54, 62, 64]. SRC family kinases have a role in smooth muscle cells reproduction and also reducing pulmonary artery tone while their inhibition result in apoptosis and raised vascular resistance. Some recent studies indicated that pathways other than SRC may also play a role in endothelial dysfunction, which leads to dasatinib-induced PAH. Animal studies showed that the levels of soluble ICAM-1, soluble VCAM-1, and soluble E-selectin, markers of endothelial dysfunction, rises with dasatinib leading to less hypoxic vasoconstriction and subsequently impaired endoplasmic reticulum function [65]. There is no specific biomarker for PAH, but brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) have been used in clinical practice to evaluate the patient’s condition before and after the treatment [66-68]. Evaluation of the 6 minute walk distance (6-MWD) and world health organization (WHO) functional class is also useful in predicting prognosis of PAH treatment [59]. In a descriptive study of PAH cases in the French pulmonary hypertension registry from November 2006 to September 30, 2010, nine patients of dasatinib-induced PAH were reported. None of them had a chronic respiratory disease, family history of PAH or history of medications with the risk of PAH. Discontinuation of dasatinib led to improvement in clinical status of all patients except 3 who required further pharmacotherapy [15]. Although PAH is clinically reversible, the hemodynamic of patients may not completely improve after discontinuation of therapy [64].

**MANAGEMENT**

Since the widespread use of TKIs has made a tremendous change in the treatment of CML, the complications associated with these medications need to be identified and managed appropriately.

**Pleural effusion**

As noted above, treatment of CML with dasatinib was associated with a high prevalence and recurrence rate of PE. In a multivariate analysis, the most significant risk factor for incidence of PE was the patient’s age [69]. Dasatinib-induced PE has a clinically ameliorative nature in most cases. Dose interruption, dose reduction and drug therapy have been suggested for PE management [50, 54]. Based on radiographic features, patients with class 1 PE do not need any intervention. In patients who are categorized in class 2 or more and are asymptomatic, treatment should be interrupted and diuretics may be started in the presence of fluid retention. Therapy of CML should be resumed after resolution of effusion. Dose should be reduced in the case of further episodes. In symptomatic patients with PE ≥ class 2 or asymptomatic patients with PE ≥ class 3, dasatinib should be discontinued and corticosteroids (prednisone 40 mg daily for...
Management of dasatinib-induced PAH and PE

Table 1. FDA approved pharmacological classes for treatment of PAH.

| Class                          | Drug          | Route of administration | Dose                                      |
|-------------------------------|---------------|-------------------------|-------------------------------------------|
| Prostacyclin derivatives      | Epoprostenol  | IV                      | Initial dose of 2 ng kg⁻¹ min⁻¹ IV infusion, titrated by 1–2 ng kg⁻¹ min⁻¹ q 15 min if tolerated |
|                               | Iloprost      | Inhaled                 | 2.5 μg inhaled, if tolerated then 5 μg, 6–9 times a day PRN; Maintenance: 2.5–3 μg dose⁻¹ (max: 45 μg daily) |
|                               | Treprostinil  | PO                      | PO: 0.125 mg TID or 0.25 mg BID, titrated by 0.125 mg TID every 3–4 days |
|                               |               | Continuous IV or SC infusion | IV or SC infusion: 1.25 ng kg⁻¹ min⁻¹ titrated by no more than 1.25 ng kg⁻¹ min⁻¹ per wk based on clinical response; after 4 wk, titrated by no more than 2.5 ng kg⁻¹ min⁻¹ per wk based on clinical response |
| Endothelin receptor antagonists | Bosentan      | Oral                    | 125 mg twice daily                          |
|                               | Ambrisentan   | Oral                    | 5 or 10 mg once daily                       |
|                               | Macitentan    | Oral                    | 10 mg once daily                            |
| Phosphodiesterase type-5 inhibitors | Sildenafil   | Oral                    | 20 mg TID                                   |
|                               | Tadalafil     | IV Injection             | 40 mg once daily                            |
| Soluble cGMP stimulators      | Tadalafil     | Oral                    | 0.5–1.0 mg TID (titrated by 0.5 mg every 2 wk as tolerated to maximum dose 2.5 mg) |
| Prostacyclin receptor agonists | Selexipag     | Oral                    | 200 mg twice daily, titrated as tolerated to maximum dose of 16,000 mg twice daily |

Abbreviations: cGMP, Cyclic guanosine monophosphate; FDA, Food and Drug Administration; h, hour; IV, Intravenous; PAH, pulmonary arterial hypertension; SC, subcutaneous.
Phosphodiesterase-5 inhibitors: Phosphodiesterase-5 (PDE-5) is the dominant isotype of PDE in the pulmonary vascular smooth cell muscles which is upregulated in PAH. It metabolizes cyclic guanosine monophosphate; hence PDE-5 inhibitors could induce nitric oxide-mediated vasodilation and possibly have some anti-proliferative effects [74, 75]. Sildenafil, tadalafil, and vardenafil have been studied in PAH and only sildenafil and tadalafil which are different in chemical structure have been approved by FDA for treatment of PAH [76, 77]. Due to the longer half-life of tadalafil (17.5 hr) as compared to that of sildenafil (~4 hr), it is prescribed once daily whereas the other is taken 3 times per day [78]. They are similar in adverse effects profile and both tadalafil and sildenafil were associated with beneficial effects in exercise tolerability, hemodynamic parameters and clinical status of dasatinib-induced PAH [79].

WHO functional class, 6-MWD, mPAP, and clinical worsening were assessed in 278 PAH patients who received either placebo or sildenafil (20 mg, 40 mg, or 80 mg) orally 3 times daily for 12 weeks. A notable improvement in all mentioned values was achieved after all doses. Since complete inhibition of PDE-5 at the dose of 20 mg 3 times was achieved, dose escalation to get much more response is not reasonable [75]. The efficacy of sildenafil in dasatinib-induced PAH has been evaluated in numerous case reports [80-84]. Groeneveldt and coworkers reported a case with mPAP of 55 mmHg and NYHA functional class 4 who had no improvement in NYHA functional class after being treated with sildenafil. Actually, dasatinib was not discontinued in spite of emphasis on stopping treatment immediately after the appearance of PAH [59, 85]. Sildenafil was also evaluated in combination with bosentan (20 mg TDS and 62.5 mg BD, respectively) in a patient with mPAP of 37 mmHg, WHO functional class 2 and BNP 685 pg mL⁻¹. All variables improved after 6 months of treatment [86]. In another case, right ventricle systolic pressure (RVSP) was reduced from 71 mmHg to 55 mmHg after treatment with 25 mg once daily sildenafil. Re-challenging of dasatinib after reduction of RVSP was associated with a faster incidence of PAH appearance [61].

In a large trial, tadalafil, another PDE-5 inhibitor, was investigated in doses of 2.5 mg, 10 mg, 20 mg and 40 mg once daily for management of PAH in 405 patients. Borg dyspnea score (BDS), 6-MWD, clinical worsening, health-related quality of life and WHO functional class were assessed. Only the 40 mg/day dose showed statistically significant improvement in all of measurements except WHO functional class and BDS [87]. Until today there is no study to evaluate tadalafil monotherapy in dasatinib-induced PAH, as it was used in combination with other drugs. An abstract published in January 2020 in European Heart Journal Cardiovascular Imaging showed that combination of tadalafil and ambrisantan is effective in improvement of systolic PAP and secondary myocardium changes caused by dasatinib [88]. Two other different dosage regimens of tadalafil and ambrisantan combination were used: "tadalafil (40 mg daily)+ambrisantan (10 mg daily)" and "tadalafil (20 mg daily)+ambrisantan (5 mg daily)". Both revealed improvement in pulmonary symptoms, mPAP, 6-MWD, BNP level and WHO functional class [62, 64].

Endothelin receptor-1 antagonists (ERAs): Bosentan, ambrisantan and macitentan are ERAs approved by FDA for management of PAH. Bosentan, the oldest member of ERAs is a non-selective competitive antagonist of endothelin receptor-1 (ET-1) that irreversibly blocks both ET-1A and ET-1B [89, 90]. The efficacy of bosentan in PAH was evaluated in BREATH-1 study. Patients were treated with 62.5 mg BD bosentan for 4 weeks and then randomly assigned to receive 125 mg or 250 mg twice daily for a minimum of additional 12 weeks. Amelioration of exercise capacity as primary outcome of the trial was seen in both bosentan-treated groups (P<0.001). Changes in the BDS, WHO functional class, and the time to clinical worsening were considered as secondary endpoints. Reduction in BDS was greater in patients received 250 mg BD bosentan versus 125 mg twice daily. In total, WHO functional class decreased 42% in patients received bosentan versus 30% in patients received placebo. Time to clinical worsening was longer in patients in bosentan group compared to patients in placebo group after 16 weeks. Hepatic dysfunction occurred in a dose dependent manner and was more frequent with 250 mg BD dosing. Surprisingly, the changes in mPAP were not clinically significant notwithstanding in study group received high dose of bosentan (250 mg BD) (88±13 mmHg at baseline versus 85±11 mmHg at the end of trial) [91]. Reversible elevation in aminotransferases, anemia, headache and edema were the complications associated with bosentan [92, 93]. The only published paper about dasatinib-induced PAH treated with bosentan was a patient with acute lymphoblastic leukemia (ALL). Titration of bosentan to a dose of 125 mg twice daily led to significant decrease in systolic pulmonary artery pressure (SPAP) and pro-BNP level. NYHA functional class and also 6-MWD significantly improved during the intervention [94].

Among above mentioned three agents, ambrisantan is a selective blocker of ET-1A which is responsible for smooth muscle cells vasoconstriction. The incidence of liver impairment and drug interactions of ambrisantan was lower but it was associated with a more frequency of peripheral edema [95-97]. Data demonstrated that selectivity on ETR blockage was not an important factor in choosing an agent for PAH management. The role of ambrisantan in combination with tadalafil in dasatinib-induced PAH was evaluated just in case reports as mentioned previously [98]. Along with discontinuation of dasatinib, ambrisantan in combination with sildenafil and treprostinil was associated with improvement.
Table 2. Cases of dasatinib-induced PAH and their pharmacotherapy.

| Study                  | N of participants/diagnosis | Age, yr/ gender, M or F | Time from dasatinib initiation to PAH diagnosis (mo) | DASA dose, mg/day | Treatment line of DASA | Concomitant PE | Intervention | Improved items |
|------------------------|-----------------------------|-------------------------|--------------------------------------------------------|-------------------|------------------------|---------------|--------------|----------------|
| Jose et al. (2017) [64]| 1, CML                     | 61, M                   | 26                                                     | 140               | Second                 | Yes           | DASA D/C     | Tad 20 mg QD and Amb 5 mg daily, The Tad was up-titrated over a period of 4 wk to 40 mg QD, followed by an up titration of Amb to 10 mg QD over the following 4 wk | After 4 mo, mPAP, PCWP, PVR, 6-MWD, WHO FC |
| Ibrahim et al. (2019) [62]| 1, CML                     | 46, F                   | 120                                                    | 70                | Second                 | Yes           | DASA D/C     | Amb 5 mg daily + Tad 20 mg QD | After 1 wk, PAP |
| Orlandi et al. (2012) [80]| 1, CML                     | 53, F                   | 31                                                     | 100               | Second                 | No            | DASA D/C     | Sil 20 mg    | After 2 mo, WHO-FC PAP, 6-MWD, After 1 mo, WHO FC, RVSP, NT-pro BNP, PAP |
| Sano et al. (2012) [81]| 1, CML                     | 61, F                   | 27                                                     | 140               | Second                 | Yes           | DASA D/C     | Sil 60 mg QD | After 3 mo, PASP, Pro BNP, 6-MWD, The patient did not improve in NYHA FC class by sildenafil and diuretics, 3 mo after substitution DASA with NIT, NYHA FC after start NIT, After 1 mo, WHO FC, PAP, BNP |
| Wang et al. (2015) [82]| 1, CML                     | 33, M                   | 63                                                     | 100               | Second                 | No            | DASA D/C     | Sil         | After 3 mo, WHO-FC PAP, BNP, After 1 mo, NYHA FC, After 9 mo, Pro BNP, 6-MWD, The patient did not improve in NYHA FC class by sildenafil and diuretics, 3 mo after substitution DASA with NIT, NYHA FC after start NIT, After 1 mo, WHO FC, PAP, BNP |
| Taço et al. (2015) [94]| 1, ALL                      | 50, M                   | 24                                                     | 140               | Second                 | Yes           | DASA D/C     | Bos 62.5 mg BID and in 2 wk increased to 125 mg BID | After 1 wk, EPO, Dyspnea |
| Groeneveldt et al. (2013) [85]| 1, CML                    | 57, M                   | 37                                                     | 70                | Second                 | No            | Sil          | DASA D/C   | After 4 mo, mPAP, PCWP, PVR, 6-MWD, After 21 mo, WHO FC, RVSP, NT-pro BNP, mPAP, PVR, 6-MWD, CO CI |
| Helgeson et al. (2016) [115]| 1, CML                    | 30, F                   | NR                                                     | 100               | Second                 | Yes           | DASA D/C     | EPO 20 mg kg⁻¹ min⁻¹ for 5 mo, then EPO 4 mg kg⁻¹ min⁻¹ for 5 mo and discontinuation with mild rebound of MPAP, therefore, Sil was initiated | After 1 wk, EPO, Dyspnea |
| Nishimori et al. (2018) [86]| 1, CML                    | 24, M                   | 48                                                     | 100               | Second                 | Yes           | DASA D/C     | Sil 20 mg  | TID + Bos 62.5 mg BID | After 1 mo, WHO FC, PAP, BNP |
| Toya et al. (2019) [104]| 1, CML and scleroderma   | 63, M                   | 36                                                     | 100               | Second                 | Yes           | DASA D/C     | Tad 40 mg QD + Mac 10 mg QD + Sel 1.2 mg BID | After 1 mo, mPAP, PVR, 6-MWD, After 21 mo, WHO FC, RVSP, NT-pro BNP, mPAP, PVR, 6-MWD, CO CI |
| Buchelli et al. (2014) [71]| 1, CML                    | 50, M                   | 48                                                     | 100               | Second                 | Yes           | DASA D/C     | Sil 20 mg TID | After 1 mo, WHO FC, RVSP, NT-pro BNP, mPAP, PVR, 6-MWD, CO CI |
### Table 2. Continued.

| Study                  | N of participants/diagnosis | Age, yr/ gender, M or F | Time from dasatinib initiation to PAH diagnosis (mo) | DASA dose, mg/day | Treatment line of DASA | Concomitant PE | Intervention | Improved items                  |
|------------------------|-----------------------------|-------------------------|----------------------------------------------------|-------------------|------------------------|----------------|--------------|----------------------------------|
| Seegobin et al. (2017) 98 | 1, CML                      | 52, M                   | 48                                                 | NR                | Second                 | Yes            | DASA D/C Amb               | NR, Symptoms as well as effusions improved |
| Daccord et al. (2018) 99 | 1, CML                      | 32, M                   | 36                                                 | NR                | Third                  | Yes            | DASA D/C PDE-5 inhibitor + ERA | NR, NYHA FC mPAP 6-MWD PVR CI |
| Dumitrescu et al. (2011) 83 | 1, CML                      | 47, M                   | 72                                                 | 100               | Second                 | Yes            | DASA D/C Sil               | After 2 mo, WHO FC PAP CO |
| Skride et al. (2017) 70 | 1, CML                      | 67, M                   | 42                                                 | 100               | Second                 | Yes            | DASA D/C Sil 20 mg TID     | NR, mPAP 6-MWD PVR CO |
| Orlikow et al. (2019) 147 | 1, CML                      | 73, F                   | 9                                                  | NR                | Second                 | Yes            | DASA D/C Nif 30 mg QD     | After 12 mo, CO CI PVR |
| Hennigs et al. (2011) 84 | 1, CML                      | 70, M                   | 32                                                 | 140               | Second                 | Yes            | DASA D/C Sil 20 mg TID     | After 10 mo, CO RVSP NT-proBNP 6-MWD Mpaap WHO FC PVR |
| Hong et al. (2015) 61  | 2, CML                      | 43, M                   | 69                                                 | 140               | Second                 | Yes            | DASAD/C Sil + CCB + Diuretics | NR, NYHA FC PAP RVSP Nif, RVSP BNP |
| 52, M                   | 38                           | 140                     | Second                                             | DASA D/C Sil 25 mg QD |                        |                |                          |                                  |
| Montani et al. (2012) 15 | 3, CML                      | 74, F                   | 33                                                 | 100               | Second                 | Yes            | DASA D/C CCB for 6 mo, then stopped | 6-MWD After 3 mo, NYHA FC, mPAP 6-MWT PVR BNP |
| 29, F                   | 36                           | 100                     | Second                                             | DASA D/C Bos     |                        |                |                          | After 2 mo, NYHA FC, After 6 mo, mPAP 6-MWT PVR |
| 39, F                   | 34                           | 100                     | Second                                             | DASA D/C Bos     |                        |                |                          | After 1 mo, NYHA FC |

Abbreviations: 6-MWD, 6-minute walk distance; ALL, acute lymphoblastic leukemia; Amb, ambrisentan; BID, two times a day; BNP, b-type natriuretic peptide; Bos, bosentan; CCB, calcium channel blocker; Cl, cardiac index; CML, chronic myeloid leukemia; CO, cardiac output; DASA, dasatinib; D/C, discontinuation; EPO, epoprostenol; ERA, endothelin receptor-1 antagonist; f, female; FC, functional classification; M, male; Mac, macitentan; mPAP, mean pulmonary artery pressure; Nif, niledipine; NII, nilotinib; NT-pro BNP, N-terminal pro b-type natriuretic peptide; NYHA, New York heart association; PAH, pulmonary arterial hypertension; PAP, pulmonary artery pressure; PASP, pulmonary artery systolic pressure; PCWP, pulmonary capillary wedge pressure; PDE-5, phosphodiesterase-5; PE, pulmonary embolism; Pro BNP, pro hormone b-type natriuretic peptide; PVR, pulmonary vascular resistance; QD, once a day; RVSP, right ventricular systolic pressure; Sel, selexipag; Sil, sildenafil; Tad, tadalafil; TID, three times a day; WHO, world health organization; WU, wood unit.
in mPAP, 6-MWD and NYHA functional class. However, an unexpected progression of PAH occurred after 3 years which was not controlled by intensive anti PAH therapy and resulted in need for lung transplantation. It is notable that the CML therapy may be resumed with nilotinib in patients with PAH following dasatinib use [99].

Macitentan is a novel non-selective ET-1 antagonist with an active metabolite with a longer half-life compared to the parent drug. Macitentan and its active metabolite have a higher tendency to tissue and bind more potently to ET receptors compared to the other ET-1As [100]. It has a good safety profile with well-tolerated adverse events including nausea, vomiting and headache and less liver toxicity compared to bosentan and ambrisentan [101]. This highly potent ERAs was studied in SERAPHIN trial with the dosage regimens of 3 mg and 10 mg once daily versus placebo in 742 PAH cases (not dasatinib-induced PAH). Both 3 mg (P=0.01) and 10 mg (P<0.0001) once daily dosing reduced the risk of morbidity/mortality by 30% and 45%, respectively. NYHA functional class and 6-MWD changes from baseline were the secondary endpoints of study. Overall, macitentan was well tolerated and adverse effects including nasopharyngitis, headache and anemia were similar in all groups [102]. It also reduced PAH-related hospitalization and chronic thromboembolic pulmonary hypertension [103]. In a case of Dasatinib-induced PAH with concurrent scleroderma, macitentan was used along with tadalafil and selexipag. Rapid improvement of mPAP, 6-MWD and NYHA functional class were reported [104].

Sitaxentan, a selective ERA, was eliminated from the market because of its lethal liver toxicity [105-107].

**Epoprostenol and prostaglandin I2 (PGI2) derivatives:**
Epoprostenol as a synthetic derivative of PGI2 received FDA approval in 1995. PGI2 acts as a direct vasodilator and also a cytoprotective agent which inhibits platelet aggregation [108-110]. Epoprostenol has beneficial effects on PAH symptoms, disease progression, 6-MWD and survival [111-115]. A case of dasatinib-induced PAH was treated successfully with epoprostenol along with discontinuation of dasatinib [116]. According to epoprostenol instability in plasma, continuous intravenous infusion (IV) is the preferred route of administration, though it is linked to catheter-related thrombosis and infection [114, 117, 118]. Other adverse effects were ascites, thrombocytopenia, flushing, headache, nausea, loose stool, jaw discomfort and musculoskeletal pain [110, 119].

Treprostinil is another prostanooid with longer half-life used in treatment of PAH. It was associated with improvement in quality of life, exercise capacity, functional class, pulmonary hemodynamics, and survival of patients [120-123]. Treprostinil can be used in oral, inhaled, subcutaneous or IV routes which the 2 latter are assumed bio-equivalent at steady state in the dose of 10 ng kg⁻¹ min⁻¹. It is also used as SC infusion. Local pain following infusion may occur and could be decreased by titrating of dose during 6 months [124, 125]. Transition from IV epoprostenol to IV or SC treprostinil is rational when patient is intolerant to epoprostenol or in the case of worsening of clinical status [126-128]. Inhaled treprostinil in patients with severe pulmonary hypertension revealed a significant sustained impact on pulmonary vascular resistance compared to the same doses of inhaled iloprost with a better tolerability profile [129]. According to a double-blind, randomized, placebo-controlled trial, continuous SC infusion of treprostinil enhances exercise capacity regardless of the PAH etiology. Considering this dose-related effect, treprostinil could be an appropriate agent for management of dasatinib-induced PAH [130].

Iloprost, an analog of PGI2 has a short half-life of 20-25 minutes and was used as inhalation or IV forms with frequent doses (e.g., 6-9 times daily) [131]. It can improve 6-MWD, Mahler dyspnea index, quality of life and NYHA functional class in PAH by inhaled formulation [132]. Despite its inhalation form, IV iloprost did not receive FDA approval for PAH. Both iloprost and treprostinil inhalation formulations lead to cough [133].

Beraprost is an oral rapid onset analog of PGI2 that improves 6-MWD, disease progression and WHO functional class. Considering WHO functional class, the beneficial effects is limited to 6 months [134]. Beraprost and Iloprost have not yet studied for management of dasatinib-induced PAH, but they could be acceptable drugs since both have proven efficacy in ameliorating the PAH with other etiologies.

Selexipag is another oral prostacyclin IP2-receptor (IP2r) agonist with a non-prostanoid structure. It has a vasodilator effect on large and small pulmonary arterial branches [135-137]. Selexipag has the highest affinity for IP2r with similar side effect profile of other IP2r agonists. Headache is the most common adverse effect along with jaw pain, nausea and diarrhea which are often observed with rapid dose-titration and are reduced over time [138]. Selexipag showed a significant improvement in the primary composite endpoint of death, complications related to PAH, pulmonary vascular resistance and 6-MWD in GRIPHON trial [136]. As mentioned previously, selexipag has been studied in dasatinib-induced PAH in combination with macitentan and tadalafil resulted in rapid improvement of mPAP, 6-MWD and NYHA functional class [104].

**Calcium channel blockers (CCBs):**
CCBs reduces the influx of calcium in smooth muscle cells leading to systemic peripheral arterial dilation. Therapeutic effects of CCBs will be obtained when used at high doses for a long time [139-143]. Among long acting nifedipine, diltiazem and amlodipine, diltiazem is preferred when the heart rate is above 80 beats min⁻¹ [144, 145]. Verapamil is not recommended due to its notable negative inotropic effect [146]. Although CCBs have been noted nearly in all PAH treatment guidelines, in fact a very few numbers of patients with PAH including idiopathic-PAH patients, genetically associated PAH, or anorexigen-induced PAH will benefit from using high doses and long term CCB therapy [147]. It doesn’t seem that CCBs are effective in dasatinib-induced PAH [148].
CONCLUSION

Pulmonary complications of TKIs need to be diagnosed and managed promptly. Dasatinib was associated with a higher prevalence and recurrence rate of PE and PAH among TKIs. In symptomatic patients with mild PE, dasatinib should be interrupted and in the case of fluid retention, diuretics should be initiated. Therapy of CML should be resumed after resolution of effusion. In asymptomatic patients with PE ≥ class 2 or asymptomatic patients with PE ≥ class 3, dasatinib should be discontinued and corticosteroids (prednisone 40 mg daily for four days) should be initiated along with therapeutic thoracentesis. PAH is a life threatening complication of long-term therapy with dasatinib. Phosphodiesterase type-5 inhibitors (e.g., sildenafil and tadalafil) alone or in combination with endothelin receptor-1 antagonists (e.g., bosentan and macitentan) and also synthetic derivatives of PGI2 or non-prostanoid prostacyclin-receptor agonist (e.g., selexipag) were successfully used in the management of dasatinib-induced PAH. Current recommendations regarding the management of pulmonary toxicities of TKIs including dasatinib are based on published case reports and evaluating the safety and efficacy of different available pharmacotherapies require conducting multi-center randomized controlled trials.

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

REFERENCES

1. Kaiafa G, Kakaletsis N, Savopoulos C, et al. Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report. J Clin Pharm Ther 2014;39:102-5.
2. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol 2018;93:442-59.
3. Radich JP, Deininger M, Abdou CN, et al. Chronic myeloid leukemia, version 1.2019. NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2018;16:1108-35.
4. Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(Suppl 4):iv1-41.5.
5. Thompson PA, Kantarjian HM, Cortes JE. Diagnosis and treatment of chronic myeloid leukemia in 2015. Mayo Clin Proc 2015;90:1440-54.
6. Larson RA. Is there a best TKI for chronic phase CML? Hematology Am Soc Hematol Educ Program 2015;2015:250-6.
7. Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol 2015;33:4210-8.
8. Shah NP, Rousselot P, Schiffer C, et al. Dasatinib in imatinib-resistant or intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180 034. Am J Hematol 2016;91:869-74.
9. Medeiros BC, Possick J, Fradley M. Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: strategies for monitoring, detecting, and managing. Blood Rev 2018;32:289-99.
10. García-Gutiérrez V, Hernández-Boluda JC. Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front Oncol 2019;9:603.
11. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872-84.
12. Efficaace F, Stango F, Iurlo A, et al. Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. Leukemia 2020;34:488-98.
13. Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol 2018;36:231-7.
14. Caldemeyer L, Dugan M, Edwards J, Akard L. Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Hematol Malig Rep 2012;7:2128-37.
15. Brixey AG, Light RW. Pleural effusions due to dasatinib. Curr Opin Pulm Med 2010;16:351-6.
16. Jasielec JK, Larson RA. Dasatinib-related pulmonary toxicity mimicking an atypical infection. J Clin Oncol 2016;34:e46-8.
17. Fazakas C, Nagaraj C, Zabini D, et al. Rho-kinase inhibition ameliorates dasatinib-induced endothelial dysfunction and pulmonary hypertension. Front Physiol 2018;9:537.
18. Huang YM, Wang CH, Huang JS, et al. Dasatinib-related chylothorax. Turk J Haematol 2015;32:68-72.
19. Bergeron A, Réa D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007;176:814-8.
20. Al-Ameri AM, Kantarjian H, Burton E, et al. Low risk of infectious events in patients (Pts) with chronic myeloid leukemia (CML) in chronic phase (CP) treated with dasatinib. Blood (ASH Annual Meeting Abstracts) 2009;114(Suppl):3291.
21. Ozgur Yurtta N, Eşkazen AE. Dasatinib-induced pulmonary arterial hypertension. Br J Clin Pharmacol 2018;84:835-45.
22. Quilot FM, Georges M, Favrot N, et al. Pulmonary hypertension associated with ponatinib therapy. Respir Med 2016;167:676-9.
23. Rium M, Seferian A, Savale L, et al. Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. Eur Respir J 2016;48:1517-9.
24. Hickey FM, Thompson AA, Chalalampopoulos A, et al. Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension. Eur Respir J 2016;48:1514-6.
25. Alkhatib Y, Albashaireh D, Al-Aqtash T, Awdish R. The role...
of tyrosine kinase inhibitor "Lapatinib" in pulmonary hypertension. Pulm Pharmacol Ther 2016;37:81-4.
27. Weatherald J, Chaumais MC, Montani D. Pulmonary arterial hypertension induced by tyrosine kinase inhibitors. Curr Opin Pulm Med 2017;23:392-7.
28. Weatherald J, Bondeelle L, Chaumais MC, et al. Pulmonary complications of Bcr-Ab1 tyrosine kinase inhibitors. Eur Respir J 2020;56:2000279.
29. Chen R, Chen B. The role of dasatinib in the management of chronic myeloid leukemia. Drug Des Devel Ther 2015;9:773-9.
30. Lindauer M, Hochhaus A. Dasatinib. In: Martens UM, ed. Small molecules in oncology. Heidelberg, Germany: Springer, 2014:27-65.
31. Rosti G, Castagnetti F, Gugliotta G, Baccarani M. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat Rev Clin Oncol 2017;14:141-54.
32. Lindauer M, Hochhaus A. Dasatinib. In: Martens UM, ed. Small molecules in hematology. Heidelberg, Germany: Springer, 2018:29-68.
33. Mughal TI, Radich JP, Deininger MW, et al. Chronic myeloid leukemia: reminiscences and dreams. Haematologica 2016;101:541-58.
34. Braden HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations. Blood 2006;108:2332-8.
35. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukaemia patients. J Clin Oncol 2016;34:2333-40.
36. Caocci G, Arzeti S, Orrù N, et al. Gynecomastia in a male after dasatinib treatment for chronic myeloid leukaemia. Leukemia 2008;22:2127-8.
37. Lundholm M, Charnogursky G. A case of dasatinib-induced hypoglycemia. Endocrine Practice 2019;25:85.
38. Aguilera DG, Tsimeridou AM. Dasatinib in chronic myeloid leukaemia: a review. Ther Clin Risk Manag 2009;5:281-9.
39. Yu L, Liu J, Huang X, Jiang Q. Adverse effects of dasatinib on hypoglycemia. Endocrine Practice 2019;25:85.
40. Kostos L, Burbury K, Srivastava G, Prince HM. Gastrointestinal bleeding in a chronic myeloid leukemia patient precipitated by dasatinib-induced platelet dysfunction: case report. Platelets 2015;26:809-11.
41. Ono Y, Mori T, Kato J, et al. Hemorrhagic colonic ulcers caused by dasatinib for chronic myelogenous leukemia. Int J Hematol 2010;92:556-8.
42. Bonvin A, Mesnil A, Nicolini FE, et al. Dasatinib-induced acute hepatitis. Leuk Lymphoma 2008;49:1630-2.
43. Dasanu CA, Padmanabhan P, Clark BA 3rd, Do C. Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use. Expert Opin Drug Saf 2012;11:445-57.
44. Kim DW, Saussele S, Williams LA, et al. Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study. Ann Hematol 2018;97:1357-67.
45. Sprycel prescribing information. New York, NY: Bristol-Myers Squibb, 2021. (Accessed July 10, 2021, at https://packageinserts.bms.com/pi/pi_sprycel.pdf).
46. Keating GM. Dasatinib: a review in chronic myeloid leukaemia and ph+ acute lymphoblastic leukaemia. Drugs 2017;77:85-96.
47. Quintás-Cardama A, Kantarjian H, O’Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-14.
48. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204-12.
49. Irulö A, Galimberti S, Abruzzese E, et al. Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. Ann Hematol 2018;97:95-100.
50. Latagliata R, Breccia M, Fava G, et al. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukemia. Hematol Oncol 2013;31:103-9.
51. Common terminology criteria for adverse events (CTCAE). Version 4.0. Bethesda, MD: National Cancer Institute, 2009.
52. Cortes JE, Saglio G, Baccarani M, et al. Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056). Blood (ASH Annual Meeting Abstracts) 2014;124(Suppl):152.
53. Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009;113:6322-9.
54. Phan C, Juttant EM, Tu L, et al. Dasatinib increases endothelial permeability leading to pleural effusion. Eur Respir J 2018;51:1701096.
55. Cortes JE, Jimenez CA, Mauro MJ, Geyer A, Pinilla-Ibarz J, Smith BD. Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management. Clin Lymphoma Myeloma Leuk 2017;17:78-82.
56. Baloch ZQ, Abbas SA, Bharti H, Braver Y, Ali SK. Dasatinib-induced chylothorax in chronic myeloid leukemia. Proc (Bayl Univ Med Cent) 2017;30:71-3.
57. Ferreiro L, San-José E, Suárez-Antelo J, Valdés L. Dasatinib-induced pleural effusion: chylothorax, an option to consider. Ann Thorac Med 2016;11:289-93.
58. Rix U, Hantschel O, Dürnberger G, et al. Chemical proteomic and genomic profiling of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007;110:4055-63.
59. El-Dabh A, Acharya D. EXPRESS: pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors. Pulm Circ 2019;9:2045894019865704.
60. Toya T, Nagatomo Y, Kagami K, et al. Computed tomography–measured pulmonary artery to aorta ratio and EUTOS score for detecting dasatinib-induced pulmonary arterial hypertension.
61. Hong JH, Lee SE, Choi SY, et al. Reversible pulmonary arterial hypertension associated with dasatinib for chronic myeloid leukemia. Cancer Res Treat 2015;47:937-42.
62. Ibrahim U, Sagib A, Dhar V, Odaimi M. Dasatinib-induced pulmonary arterial hypertension - a rare late complication. J Oncol Pharm Pract 2019;25:727-30.
63. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D34-41.
64. Jose A, Rafei H, Ahari J. Combination targeted pulmonary hypertension therapy in the resolution of dasatinib-associated pulmonary arterial hypertension. Pulm Circ 2017;7:803-7.
65. Guignabert C, Phan C, Severian A, et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest 2016;126:3207–18.
66. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPcC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016;37:67-119.
67. Minami M, Arita T, Iwasaki H, et al. Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib. Br J Haematol 2017;177:578-87.
68. Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. Eur Respir J 2008;32:503-12.
69. Hughes TP, Laneuville P, Rousselot P, et al. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica 2019;104:93-101.
70. Skride A, Sablinski S, Sablinski K, Lesina K, Leijnies A, Leijnse S. Pulmonary arterial hypertension in a patient treated with dasatinib: a case report. J Med Case Rep 2017;11:362.
71. Buchelli Ramirez HL, Álvarez Álvarez CM, Rodríguez Reguero JJ, García Clemente MM, Casan Clarà P. Reversible pre-capillary pulmonary hypertension due to dasatinib. Respir Care 2014;59:e77-80.
72. Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014;123:494-500.
73. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. Chest 2019;155:565-86.
74. Jernigan NL, Resta TC. Chronic hypoxia attenuates cGMP-dependent pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol 2002;282:1:1366-75.
75. Galiè N, Ghofrani HA, Torbicicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.
76. Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004;44:1488-96.
77. Montani D, Chaumaïs MC, Savale L, et al. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther 2009;26:813-25.
78. Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract 2006;60:967-75.
79. Montani D, Chaumaïs MC, Guignabert C, et al. Targeted therapies in pulmonary arterial hypertension. Pharmacol Ther 2014;141:172-91.
80. Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res 2012;36:e4-6.
81. Sano M, Sotome M, Urushida T, et al. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-. Intern Med 2012;51:2337-40.
82. Wang HC, Lee CS, Liu TC. Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography. Kaohsiung J Med Sci 2015;31:165-6.
83. Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukemia. Eur Respir J 2011;38:218-20.
84. Hennigs JK, Keller G, Baumann HJ, et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 2011;11:30.
85. Groeneveldt JA, Gans SJ, Bogaard HJ, Vonk-Noordegraaf A. Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition. Eur Respir J 2013;42:869-70.
86. Nishimori M, Honjo T, Kailbotsu K, et al. Dasatinib-induced pulmonary arterial hypertension treated with upfront combination therapy. Carpe Rep Cardiol 2018;2018:3895197.
87. Galìè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. N Engl J Med 2012;366:2148-57.
88. Fernandez Valledor A, Cepas Guillen P, Izquierdo M, et al. P1721 reversible heart right failure. Pulmonary hypertension induced by tyrosine kinase inhibitors. Eur Heart J Cardiovasc Imaging 2020;21(Suppl 1):jze219, 1083.
89. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994;270:228-35.
90. Grogan B, Jürgensen J, Papsdorf G, et al. Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers. J Biol Chem 2004;279:27679-87.
91. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
92. Dhillon S, Keating GM. Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension. Am J Cardiovasc Drugs 2009;9:331-50.
93. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007;30:338-44.
94. Taçoğ G, Çengel A, Özkurt ZN, Türkoğlu S. Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report. Turk Kardiyl Dern Ars 2015;43:78-81.

95. Frank H, Milczoch J, Huber K, Schuster E, Guttner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997;112:714-21.

96. McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009;135:122-9.

97. Trow TK, Taichman DB. Endothelin receptor blockade in the management of pulmonary arterial hypertension: selective and dual antagonism. Respir Med 2009;103:951-62.

98. Seegobin K, Babbar A, Ferreira J, Lyons B, Cury J, Seeram V. A case of worsening pulmonary arterial hypertension and pleural effusions by bosutinib after prior treatment with dasatinib. Pulm Circ 2017;7:808-12.

99. Daccord C, Letovanec I, Yerly P, et al. First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension. Eur Respir J 2018;51:1701694.

100. Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008;327:736-45.

101. Cadenas-Menández S, Álvarez Vega P, Oterino Manzanas A, et al. Evolution of patients with pulmonary arterial hypertension starting macitentan after the discontinuation of other endothelin-receptor antagonists: results of a retrospective study. Am J Cardiovasc Drugs 2020;20:481-7.

102. Rubin I, Pulido T, Channick R, et al. Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension (PAH): results from the SERAPHIN trial. Chest (Meeting Abstracts) 2012;142(Suppl):1026A.

103. Wong AK, Channick RN. Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update. Drug Healthc Patient Saf 2019;11:71-85.

104. Toya T, Nagatomo Y, Kagami K, Adachi T. Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report. Eur Heart J Case Rep 2019;3:ytz025.

105. Dupuis J, Hooper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008;32:407-15.

106. Gallè N, Hooper MM, Gibbs JS, Simonneau G. Liver toxicity of sitaxsentan in pulmonary arterial hypertension. Eur Respir J 2011;37:475-6.

107. Lee WT, Kirkham N, Johnson MK, Lordan JL, Fisher AJ, Peacock AJ. Sitaxsentan-related acute liver failure in a patient with pulmonary arterial hypertension. Eur Respir J 2011;37:472-4.

108. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997;96:2782-4.

109. Demling RH, Smith M, Gunther R, Gee M, Flynn J. The effect of prostacyclin infusion on endotoxin-induced lung injury. Surgery 1981;89:257-63.

110. Jacobs W, Vonk-Noordegraaf A. Epoprostenol in pulmonary arterial hypertension. Expert Opin Drug Metab Toxicol 2009;5:83-90.

111. Jones DK, Higenbottam TW. Wallwork J. Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin). Br Heart J 1987;57:270-8.

112. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990;112:485-91.

113. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1184-7.

114. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.

115. Helgeson S, Imam JS, Burger C. Severe PAH secondary to dasatinib: PAH treatment required? Chest (Meeting Abstracts) 2016;150:1218A.

116. Helgeson S. Pulmonary arterial hypertension: case report. Reactions 2016;1632:107-17.

117. Badesch DB, Tapsen VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34.

118. Kallen AJ, Lederman E, Balaji A, et al. Bloodstream infections in patients given treatment with intravenous prostanooids. Infect Control Hosp Epidemiol 2008;29:342-9.

119. Chin KM, Channick RN, de Lemos JA, Kim NH, Torres F, Rubin LJ. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension. Chest 2009;135:130-6.

120. Skoro-Sajer N, Lang I, Naeije R. Treprostinil for pulmonary hypertension. Vasc Health Risk Manag 2008;4:507-13.

121. Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006;129:1636-43.

122. Tapsen VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 2006;129:683-8.

123. Benza RL, Rayburn BK, Tallaj JA, Pamboukian SV, Bourge RC. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan. Chest 2008;134:139-45.

124. Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004;44:209-14.

125. Sadushi-Kolici R, Skoro-Sajer N, Zimmer D, et al. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. J Heart Lung Transplant 2012;31:735-43.

126. Gomberg-Maitland M, Tapsen VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005;
127. Rubenfire M, McLaughlin VV, Allen RP, et al. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest 2007;132: 757-63.

128. Vachiéry JL, Hill N, Zwicke D, Barst R, Blackburn S, Naeije R. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 2002; 121:1561-5.

129. Voswinckel R, Enke B, Reichenberger F, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 2006;48:1672-81.

130. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4.

131. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000;342:1866-70.

132. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9.

133. Krishnan U, Takatsuki S, Ivy DD, et al. Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children. Am J Cardiol 2012;110:1704-9.

134. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119-25.

135. Sorensen LM, Wehland M, Kruger M, et al. A special focus on selexipag-treatment of pulmonary arterial hypertension. Curr Pharm Des 2017;23:5191-9.

136. Sibson O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015;373:2522-33.

137. Kuwano K, Hashino A, Noda K, Kosugi K, Kuwabara K. A long-acting and highly selective prostacyclin receptor agonist prodrg, 2-4-[[5,6-diphenylpyrazin-2-yl]((isopropyl)amino)butoxy]-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, 4-[[5,6-diphenylpyrazin-2-yl]((isopropyl)amino)butoxy]acetic acid (MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther 2008;326:691-9.

138. Simonneau G, Hwang JJ, Teal S, Galie N. Incidence of subdural hematoma in patients with pulmonary arterial hypertension (PAH) in two randomized controlled clinical trials. Eur Respir J 2012;40(Suppl):P941.

139. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987;76:135-41.

140. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537.

141. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.

142. Montani D, Savale L, Natali D, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J 2010;31:1898-907.

143. Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013;62:D60-72.

144. Barst RJ, Gibbs JSR, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(Suppl 1):S78-84.

145. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.

146. Packer M, Medina N, Yushak M, Wiener I. Detrimental effects of verapamil in patients with primary pulmonary hypertension. Br Heart J 1984;52:106-11.

147. Orlikow E, Weatherald J, Hirani N. Dasatinib-induced pulmonary arterial hypertension. Can J Cardiol 2019;35:1604, e1-e3.

148. Schilz R, Rich S. Calcium channel blocker therapy: when a drug works, it works. When it doesn’t, it doesn’t. Adv Pulm Hypertens 2017;15:184-9.